Slide 1: Butterfly Network Q3 2024 Earnings Call
Butterfly Network Q3 2024 Earnings Call November 1, 2024
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Our actual results may differ from our expectations, estimates, and projections and, consequentl
Slide 3: 2024 Strategic Pillars
2024 Strategic Pillars Strengthen Core Expand Differentiate Generate ● Transform standard of ● Continue investing in our ● Improved 2024 Guidance: ● Penetrate further into care through new Ultrasound-on-Chip™ $79-$81mm or over 20% Hospitals, Clinic, Veterinary, Med Schools, applications and AI growth
Slide 4: Validating Butterfly's strong ROI.
Validating Butterfly’s strong ROI. For Enterprises For Individuals 4 https://ir.butterflynetwork.com/News/clinical-evidence
Slide 5: Medical Education Momentum Continues with ScanLab
Medical Education Momentum Continues with ScanLab™ https://www.prnewswire.com/news-releases/kansas-city-university-sets-new-standard-in- point-of-care-ultrasound-education-with-ai-guided-training-curriculum-302268356.html 5
Slide 6: International Expansion
International Expansion ● Opened new markets in Indonesia, the Continue to work with Kansas State University and Netherlands, and Belgium. Beef Cattle Institute (BCI) to disseminate findings on ● Launched iQ3 in Europe, with a value of POCUS for managing Bovine Respiratory well-attended launch event
Slide 7: Signed new partners and announced second education application
Signed 2 new partners and announced the commercial launch of a second education application! 7
Slide 8: Welcome, Steve Cashman!
Welcome, Steve Cashman! Executive Vice President Chief Business Officer Butterfly Network 8
Slide 9: Record Quarterly Revenue, Improved Full Year Adjusted EBITDA Guidance
Record Quarterly Revenue Improved Full Year Adjusted EBITDA Guidance USD (millions) Q3 2024 Q3 2023** Change Revenue $20.6 $15.4 33% Gross Margin 59.5% 60.8% (1.3) pts Operating expense $29.5 $41.9 (30%) Adjusted EBITDA Loss* $(8.4) $(12.5) 33% Cash, Cash Equivalents and Restricted Cash $97.8 $138.7
Slide 10: Butterfly March 2024 Investor Day Key Takeaways
Butterfly March 2024 Investor Day Key Takeaways Butterfly Garden and Butterfly has a Butterfly is leading a Powered by Butterfly HomeCare business digital ultrasound will contribute to plan in place, and is revolution with its meaningful revenue actively initiating robust R&D roadmap. generation over the
Slide 11: Update on the EU's RoHS Directive Efforts
Update on the EU’s Restriction of Hazardous Substances (RoHS) Directive Efforts 45-65% <0.1% RoHS limit 0.1% Content of lead in homogeneous material (% weight). Read the 2020 Exemption Renewal Form for Lead in Crystal Ultrasound Transducers: https://s27.q4cdn.com/524696391/files/doc_downloads/2024/10/
Slide 12: Butterfly March 2024 Investor Day Key Takeaways
Butterfly March 2024 Investor Day Key Takeaways Butterfly Garden and Butterfly has a Butterfly is leading a Powered by Butterfly HomeCare business digital ultrasound will contribute to plan in place, and is revolution with its meaningful revenue actively initiating robust R&D roadmap. generation over the
Slide 13: A New Paradigm for Ultrasound-on-Chip Powered Innovation
A New Paradigm for Ultrasound-on-Chip™ Powered Innovation 13
Slide 14: Thank you! Questions?
Thank you! Questions? 14